Codrituzumab (GC33) is a humanized monoclonal antibody that selectively targets glypican-3 (GPC3), a cell surface oncofetal protein predominantly expressed in hepatocellular carcinoma (HCC). This antibody demonstrates a high affinity for GPC3, with a dissociation constant (Kd) of 0.673 nM, indicating strong and specific binding. Codrituzumab functions by inducing antibody-dependent cellular cytotoxicity (ADCC), leading to the inhibition of tumor growth in affected cellular models. This makes it a valuable tool for research focused on cancer biology, particularly in studies investigating the mechanisms of immune response in liver cancer.
Codrituzumab (GC33) is a humanized monoclonal antibody that selectively targets glypican-3 (GPC3), a cell surface oncofetal protein predominantly expressed in hepatocellular carcinoma (HCC). This antibody demonstrates a high affinity for GPC3, with a dissociation constant (Kd) of 0.673 nM, indicating strong and specific binding. Codrituzumab functions by inducing antibody-dependent cellular cytotoxicity (ADCC), leading to the inhibition of tumor growth in affected cellular models. This makes it a valuable tool for research focused on cancer biology, particularly in studies investigating the mechanisms of immune response in liver cancer.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
